About Dr. Yin Xin
Dr. Yin Xin (殷欣) is a Chief Physician (主任医师) in the Department of Hepatic Oncology at Zhongshan Hospital, Fudan University, and holds a doctoral degree in Gastroenterology from Fudan University. With deep expertise spanning pancreatic cancer, gastrointestinal tumors, and hepatobiliary-pancreatic malignancies, Dr. Yin is particularly recognized for her mastery of minimally invasive and interventional treatments for primary and secondary liver cancer.
Dr. Yin performs a high annual volume of liver cancer interventional and local ablative procedures, making her one of Shanghai's most experienced practitioners in this specialized field. Her clinical approach combines precise diagnostic assessment with a broad therapeutic toolkit — from systemic oncology to image-guided local therapies — enabling her to design comprehensive, individualized treatment plans for patients with complex hepatic and pancreatic malignancies.
Clinical Expertise
- Primary liver cancer (hepatocellular carcinoma, HCC) — comprehensive management including interventional therapy, systemic treatment, and multidisciplinary coordination
- Secondary liver cancer (liver metastases) — from colorectal, pancreatic, gastric, and other primary tumors; local and systemic treatment strategies
- Minimally invasive liver cancer treatment — transarterial chemoembolization (TACE), transarterial radioembolization (TARE/Y-90), and hepatic arterial infusion chemotherapy (HAIC)
- Local ablative therapies — radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation for small or strategically located liver tumors
- Pancreatic cancer — systemic and interventional treatment for pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors
- Gastrointestinal tumors — gastric cancer, colorectal cancer, esophageal cancer, and biliary tract tumors with hepatic involvement
- Targeted therapy & immunotherapy — sorafenib, lenvatinib, regorafenib, atezolizumab + bevacizumab, and other approved regimens for advanced HCC and GI malignancies
Why Dr. Yin Xin?
For patients with liver cancer — whether primary HCC or metastatic disease — the availability of minimally invasive local therapies can be transformative. Dr. Yin's high-volume experience with TACE, HAIC, ablation, and radioembolization means that patients who are not candidates for surgery, or who need to control hepatic disease while receiving systemic therapy, have access to a full range of effective local treatment options.
Her dual expertise in interventional oncology and systemic medical oncology is particularly valuable for patients with hepatic metastases from pancreatic or gastrointestinal primaries — a population that often requires simultaneous management of the primary tumor and liver disease. Dr. Yin's ability to coordinate both dimensions of care within Zhongshan Hospital's multidisciplinary framework ensures that patients receive a coherent, integrated treatment strategy rather than fragmented care.
Zhongshan Hospital's hepatic oncology department is one of the busiest and most experienced in China, with a long track record in liver cancer research and treatment innovation. Dr. Yin's position within this department gives her patients access to the latest clinical trials, novel interventional techniques, and a multidisciplinary tumor board that reviews complex cases weekly.
Hospital: Zhongshan Hospital, Fudan University
Zhongshan Hospital is one of China's most prestigious academic medical centers, consistently ranked among the top hospitals in the country. Affiliated with Fudan University School of Medicine, it is internationally recognized for its hepatology, liver surgery, and oncology programs. The hospital's liver cancer center — one of the largest in Asia — integrates hepatic surgery, interventional radiology, medical oncology, and radiation oncology under one roof, enabling seamless multidisciplinary care. Zhongshan Hospital is also a major clinical trials hub, with active participation in international studies on HCC, GI cancers, and novel interventional techniques.
About Liver Cancer & Minimally Invasive Treatment
Liver cancer is the sixth most common cancer and the third leading cause of cancer death worldwide, with particularly high incidence in Asia due to hepatitis B prevalence. Key facts for international patients:
- Primary liver cancer (HCC): most commonly arises in the setting of chronic hepatitis B or C, cirrhosis, or metabolic liver disease; treatment depends on tumor size, number, liver function, and portal hypertension
- TACE (transarterial chemoembolization): the most widely used interventional treatment for intermediate-stage HCC; delivers chemotherapy directly to the tumor while blocking its blood supply
- HAIC (hepatic arterial infusion chemotherapy): increasingly used for advanced HCC with portal vein invasion; delivers high-dose chemotherapy via an arterial catheter with lower systemic toxicity
- Y-90 radioembolization (TARE): delivers targeted radiation to liver tumors via microspheres; effective for both HCC and liver metastases
- Ablation (RFA/MWA): curative-intent treatment for small HCC (≤3 cm); can be performed percutaneously under ultrasound or CT guidance
- Systemic therapy: atezolizumab + bevacizumab is the current first-line standard for advanced HCC; lenvatinib and sorafenib are alternatives; second-line options include regorafenib and cabozantinib
- Liver metastases: colorectal liver metastases are potentially curable with resection or ablation; pancreatic and gastric liver metastases are managed with systemic therapy ± local treatment for symptom control or disease stabilization
What to Prepare Before Your Consultation
To enable Dr. Yin's team to conduct a thorough remote case review, international patients should prepare:
- CT scan of the abdomen with contrast (arterial and portal venous phases, DICOM format, within 3 months)
- MRI of the liver with gadolinium contrast if available (preferred for HCC characterization)
- AFP (alpha-fetoprotein), CA 19-9, CEA, and liver function tests (Child-Pugh score if available)
- Hepatitis B surface antigen, hepatitis C antibody, and viral load if applicable
- Pathology report and biopsy results if available
- Summary of prior treatments (TACE, ablation, systemic therapy) with response assessments
- Current medications, especially anticoagulants or antiviral therapy
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) coordinates access to Dr. Yin Xin and the Zhongshan Hospital hepatic oncology team for international patients. Our services include:
- Remote case review and pre-consultation assessment before you travel
- Priority appointment scheduling with Dr. Yin's team
- Full translation of medical records, imaging reports, and treatment plans
- In-hospital accompaniment by a dedicated English-speaking case manager
- Accommodation, airport transfer, and logistics coordination in Shanghai
- Post-discharge follow-up and remote consultation support after returning home
Contact us to begin your case review:
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 comments